SWOG clinical trial number
S9925
Lung Cancer Specimen Repository Protocol, Ancillary
Closed
Phase
Research committees
Lung Cancer
Eligibility Criteria Expand/Collapse
For patients enrolled to and eligible for the following Southwest Oncology Group coordinated lung cancer treatment protocols: SWOG-8805, SWOG-9019, SWOG-9416, SWOG-9509, S9900, S0003, S0023, S0126, S0124, S0220, S0222, S0327, S0339, S0310, S0342, S0341, S0435, S0509, S0429, S0526, S0533, and S0536. Patients subsequently found to be ineligible for the therapeutic protocol to which they are registered will be declared ineligible for this protocol. Patients must submit specimens for this study as defined for the respective treatment study in Sections 4.0 (General) and 10.0 (Specific). The adequacy of the tissue specimen will be determined at the time the specimen arrives at the Repository. Minimum requirements for this study may be found in Appendix 10.0 of the protocol. Consent for specimen submission will be obtained and documented with consent for the appropriate treatment protocol.
This study has been approved by NCI's Central Institutional Review Board.
This study has been approved by NCI's Central Institutional Review Board.
Other Clinical Trials
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open
SWOG Clinical Trial Number
CTSU/A081801
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Research Committee(s)
Lung Cancer
Activated
06/23/2020
Open
Phase